Samuel J. Daniels

1.3k total citations · 1 hit paper
18 papers, 903 citations indexed

About

Samuel J. Daniels is a scholar working on Epidemiology, Hepatology and Pathology and Forensic Medicine. According to data from OpenAlex, Samuel J. Daniels has authored 18 papers receiving a total of 903 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 9 papers in Hepatology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Samuel J. Daniels's work include Liver Disease Diagnosis and Treatment (11 papers), Liver physiology and pathology (5 papers) and Liver Diseases and Immunity (4 papers). Samuel J. Daniels is often cited by papers focused on Liver Disease Diagnosis and Treatment (11 papers), Liver physiology and pathology (5 papers) and Liver Diseases and Immunity (4 papers). Samuel J. Daniels collaborates with scholars based in Denmark, United States and Sweden. Samuel J. Daniels's co-authors include M.A. Karsdal, Mette Juul Nielsen, Diana Julie Leeming, Signe Holm Nielsen, N.S. Gudmann, Sarah Rank Rønnow, Tina Manon‐Jensen, Detlef Schuppan, Anne Sofie Siebuhr and Lasse Langholm and has published in prestigious journals such as Circulation, Hepatology and Advanced Drug Delivery Reviews.

In The Last Decade

Samuel J. Daniels

17 papers receiving 888 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The good and the bad collagens of fibrosis – Their role in signaling and organ function

2017 363 citations M.A. Karsdal, Signe Holm Nielsen et al. Advanced Drug Delivery Reviews profile →

Peers

Countries citing papers authored by Samuel J. Daniels

Since Specialization

Citations

This map shows the geographic impact of Samuel J. Daniels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel J. Daniels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel J. Daniels more than expected).

Fields of papers citing papers by Samuel J. Daniels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel J. Daniels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel J. Daniels. The network helps show where Samuel J. Daniels may publish in the future.

Co-authorship network of co-authors of Samuel J. Daniels

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel J. Daniels. A scholar is included among the top collaborators of Samuel J. Daniels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel J. Daniels. Samuel J. Daniels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Glucagon-like peptide-1 receptor agonism and end-organ protection 2025 ·Trends in Endocrinology and Metabolism ·Samuel J. Daniels, Cecilia Karlsson, Patrick Schrauwen, Victoria Parker	3
2	Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study 2025 ·Contemporary Clinical Trials Communications ·Samuel J. Daniels, Karin Nelander, John Eriksson, Lutz Jermutus, Jelena Saillard, (unknown), Federica Tavaglione, Marco Arrese, (unknown), Umberto Vespasiani‐Gentilucci, Naim Alkhouri, Jenny E. Blau	0
3	Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo‐Controlled Study 2024 ·Journal of the American Heart Association ·(unknown), Ann‐Charlotte Egnell, Magnus Åstrand, Samuel J. Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen	1
4	Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis 2024 ·Clinical Gastroenterology and Hepatology ·Sudha S. Shankar, Samuel J. Daniels, Darren Robertson, (unknown), José Sánchez, (unknown), Lutz Jermutus, Benjamin Challis, Arun J. Sanyal	21
5	Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease 2024 ·Diabetes/Metabolism Research and Reviews ·Federica Tavaglione, (unknown), (unknown), Paolo Gallo, (unknown), (unknown), Antonio De Vincentis, Andrea Palermo, (unknown), Giovanni Galati, Nicola Napoli, Samuel J. Daniels, Jenny E. Blau, Björn Carlsson, Yeganeh Manon Khazrai, Raffaele Antonelli Incalzi, Antonio Picardi, Umberto Vespasiani‐Gentilucci	8
6	Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction (UDFF) in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease 2024 ·Digestive and Liver Disease ·Federica Tavaglione, (unknown), (unknown), Paolo Gallo, E. Capparelli, (unknown), Antonio De Vincentis, Andrea Palermo, (unknown), Giovanni Galati, Nicola Napoli, Samuel J. Daniels, Jenny E. Blau, Björn Carlsson, Yeganeh Manon Khazrai, Raffaele Antonelli Incalzi, Antonio Picardi, Umberto Vespasiani‐Gentilucci	1
7	Abstract 13097: Safety, Pharmacokinetics, and Pharmacodynamics of AZD3366 Alone and in Combination With Aspirin and Ticagrelor in Healthy Subjects 2022 ·Circulation ·(unknown), Ann‐Charlotte Egnell, Magnus Åstrand, Samuel J. Daniels, (unknown), Carl Whatling, Ola Fjellström, Anders Gabrielsen	1
8	Stage-dependent expression of fibrogenic markers in alcohol-related liver disease 2022 ·Pathology - Research and Practice ·(unknown), Maja Thiele, Aleksander Krag, Samuel J. Daniels, Diana Julie Leeming, M.A. Karsdal, Sönke Detlefsen	10
9	Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis 2020 ·Alimentary Pharmacology & Therapeutics ·Ida Falk Villesen, Samuel J. Daniels, Diana Julie Leeming, M.A. Karsdal, Mette Juul Nielsen	45
10	Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis 2020 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Samuel J. Daniels, Diana Julie Leeming, Sönke Detlefsen, (unknown), Sara Toftegaard Hjuler, Kim Henriksen, Peter Hein, Aleksander Krag, M.A. Karsdal, Mette Juul Nielsen, Sarah Brockbank, Simon Cruwys	4
11	Collagen biology and non‐invasive biomarkers of liver fibrosis 2020 ·Liver International ·M.A. Karsdal, Samuel J. Daniels, Signe Holm Nielsen, Cecilie L. Bager, Daniel Guldager Kring Rasmussen, Rohit Loomba, Rambabu Surabattula, Ida Falk Villesen, Yi Luo, Diane E. Shevell, N.S. Gudmann, Mette Juul Nielsen, Jacob George, Rose Christian, Diana Julie Leeming, Detlef Schuppan	131
12	Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue 2019 ·Biomedicine & Pharmacotherapy ·Samuel J. Daniels, Diana Julie Leeming, Sönke Detlefsen, (unknown), Sara Toftegaard Hjuler, Kim Henriksen, Peter Hein, M.A. Karsdal, Sarah Brockbank, Simon Cruwys	17
13	Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis? 2019 ·Hepatology ·M.A. Karsdal, Sönke Detlefsen, Samuel J. Daniels, Mette Juul Nielsen, Aleksander Krag, Detlef Schuppan	32
14	Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders 2018 ·Translational Oncology ·Signe Holm Nielsen, Nicholas Willumsen, Diana Julie Leeming, Samuel J. Daniels, Susanne Brix, M.A. Karsdal, Federica Genovese, Mette Juul Nielsen	65
15	ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis 2018 ·Hepatology ·Samuel J. Daniels, Diana Julie Leeming, Mohammed Eslam, Ahmed M. Hashem, Mette Juul Nielsen, Aleksander Krag, M.A. Karsdal, Jane I. Grove, Indra Neil Guha, Takumi Kawaguchi, Takuji Torimura, Duncan McLeod, Jun Akiba, Philip Kaye, Bastiaan de Boer, Guruprasad P. Aithal, Leon A. Adams, Jacob George	179
16	The good and the bad collagens of fibrosis – Their role in signaling and organ function breakdown → 2017 ·Advanced Drug Delivery Reviews ·M.A. Karsdal, Signe Holm Nielsen, Diana Julie Leeming, Lasse Langholm, Mette Juul Nielsen, Tina Manon‐Jensen, Anne Sofie Siebuhr, N.S. Gudmann, Sarah Rank Rønnow, Jannie Marie Bülow Sand, Samuel J. Daniels, Joachim Høg Mortensen, Detlef Schuppan	363
17	Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with non-alcoholic fatty liver disease 2017 ·Journal of Hepatology ·Samuel J. Daniels, Morten Nielsen, Aleksander Krag, Mohammed Eslam, M.A. Karsdal, D.J. Leeming, Joseph George	5
18	Periodic Acid-Schiff Reaction, a Useful Index of Duration of Complete Remission in Acute Childhood Lymphocytic Leukemia 1974 ·Acta Haematologica ·A Feldges, Rhomes J. A. Aur, Manuel S. Verzosa, Samuel J. Daniels	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact